Targeting minimal residual disease: a path to cure?
Nature Reviews Cancer 18, 255 (2018).
doi:10.1038/nrc.2017.125
Authors: Marlise R. Luskin, Mark A. Murakami, Scott R. Manalis & David M. Weinstock
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Marlise R. Luskin Mark A. Murakami Scott R. Manalis David M. Weinstock Tags: Perspectives Source Type: research